The role of rosiglitazone treatment in the modulation of islet hormones and hormone-like peptides: a combined in situ hybridization and immunohistochemical study

• Published in: Journal of molecular histology Vol. 39; no. 6; pp. 635 - 642
• Main Authors: Yildirim, Sukriye, Bolkent, Sema, Sundler, Frank
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 01.12.2008; Springer Nature B.V
• Subjects: Animals; Basic Medicine; Biomedical and Life Sciences; Biomedicine; Cell and Molecular Biology; Cell Biology; Cell- och molekylärbiologi; Developmental Biology; Diabetes Mellitus, Experimental; Diabetic rats; Hormones - metabolism; Hypoglycemic Agents - pharmacology; Immunohistochemistry; In Situ Hybridization; Islet hormones; Islets of Langerhans - cytology; Islets of Langerhans - drug effects; Islets of Langerhans - metabolism; Life Sciences; Male; Medical and Health Sciences; Medicin och hälsovetenskap; Medicinska och farmaceutiska grundvetenskaper; Original Paper; Peptides - metabolism; PPAR gamma - agonists; Rats; Rats, Wistar; Rosiglitazone; situ hybridization; Thiazolidinediones - pharmacology; Immunohistochemistry; Rosiglitazone; Islet hormones; Diabetic rats; In situ hybridization
• ISSN: 1567-2379; 1567-2387
• DOI: 10.1007/s10735-008-9204-z

Rosiglitazone, peroxisome proliferator-activated receptor-gamma agonist, is an insulin sensitizing agent in peripheral tissues. This study investigated islet hormones and hormone-like peptides expression patterns in rosiglitazone treated streptozotocin (STZ)-diabetic rats by using immunohistochemistry and in situ hybridization methods. Animals were divided into four groups. I. Group: Intact control rats. II. Group: Rosiglitazone-treated controls. III. Group: STZ-diabetic rats. IV. Group: Rosiglitazone-treated diabetic animals. Rosiglitazone was given for 7 days at a dose of 20 mg/kg body weight. In the STZ-diabetic group, there were significant differences in islet hormones and hormone like peptides cell numbers compared to rosiglitazone control group and intact control group. There were significant differences in cocaine- and amphetamine-regulated transcript (CART) and pancreatic polypeptide (PP) cell numbers between rosiglitazone control group and rosiglitazone + STZ-diabetic group. We detected a significant decrease in glucagon mRNA signals in rosiglitazone-treated control group compared to intact controls. We found a statistically significant difference in islet amyloid polypeptide (IAPP) mRNA signals between the STZ-diabetic group and the rosiglitazone + STZ-diabetic group. Besides, we also demonstrated co-localization of peptides by using double and triple histochemistry. In conclusion, our results show that short-term rosiglitazone treatment had a preservative effect to some extent on the expression of islet hormones and hormone-like peptides to maintain the islet function.